Tricia Neuman, ScD, director of the Kaiser Family Foundation's Program on Medicare Policy and the Project on Medicare's Future, discussed patient access to expensive treatments and the barriers to improving transparency.
Tricia Neuman, ScD, director of the Kaiser Family Foundation's Program on Medicare Policy and the Project on Medicare's Future, discussed patient access to expensive treatments and the barriers to improving transparency.
Transcript (modified)
There are lawsuits coming out because patients cannot get access to hepatitis C drugs because of the cost. What policies can be implemented to help patients get access to life-saving, but expensive drugs?
Well, that’s a real dilemma. Making sure people have access to life-saving drugs is really what this debate is all about, or at least a large part of what this debate is all about. Price is a factor.
When you look at what states are dealing with, what plans are dealing with, what employers are dealing with, if the price doesn’t come down, the only thing they feel they can do is limit access to the drug. And this means triaging—making sure that people who are most likely to benefit get access to the drugs first. But unless price comes down, I think we will continue to see the people who hope to benefit and who want to benefit from these high-priced drugs facing cost-based barriers to coverage.
What can be done to improve transparency into the process of how drugs are priced?
There’s so much interest right now in transparency and there are a number of states that have initiatives that would, in some ways, simply require companies to provide more information about the development of the drugs, the cost of the drugs, marketing, etc. But even transparency proposals are considered highly controversial, and the pharmaceutical industry has been lobbying pretty aggressively against them for various reasons.
So while there is interest in transparency and while it may seem fairly benign, transparency laws have had a hard time making it through the process.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More